Sumitomo Pharma America Announces FDA Approval of GEMTESA for Overactive Bladder
January 2, 2025
Sumitomo Pharma America, announced today that the U.S. Food and Drug Administration (FDA) has approved GEMTESA (vibegron), a beta-3 (β3) adrenergic receptor agonist, dosed once-daily (75